Allarity Therapeutics Completes Oversubscribed Rights Issue
10 juin 2021 18h01 HE
|
Allarity Therapeutics A/S
– Allarity raises SEK 102.8 million before issue costs to further finance the development of three high-priority pipeline programs – The Rights Issue of Units was subscribed for approximately 106...
Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic
09 juin 2021 05h08 HE
|
Allarity Therapeutics A/S
– Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib – Poster provides new details of the DRP® companion diagnostic for dovitinib,...
Allarity Therapeutics Publishes Interim Report for the Period January – March 2021
28 mai 2021 07h45 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (28 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – March 2021. The...
Allarity Therapeutics Publishes Prospectus Supplement
27 mai 2021 09h21 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (27 May 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the Company’s Board of Directors has approved a Supplement to the...
Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics
21 mai 2021 01h00 HE
|
Allarity Therapeutics A/S
US $20 million investment by 3i Fund is conditioned upon completion of the recapitalization into a newly organized Delaware holding company (Allarity Therapeutics, Inc.) and a listing of its common...
Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue
19 mai 2021 02h30 HE
|
Allarity Therapeutics A/S
- Proceeds will finance further development of three high-priority programs - More than SEK 100 million covered by subscription undertakings and guarantee commitments Press release Hørsholm,...
Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue
05 mai 2021 17h11 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (5 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced an update of the preliminary timetable for the planned Rights Issue announced on...
Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress
29 avr. 2021 10h31 HE
|
Allarity Therapeutics A/S
- Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib,...
MINUTES OF ANNUAL GENERAL MEETING 2021
15 avr. 2021 15h00 HE
|
Allarity Therapeutics A/S
On 15 April 2021 at 15:00 (CEST), the annual general meeting (the "General Meeting") of Allarity Therapeutics A/S, company registration (CVR) no. 28 10 63 51 (the "Company"), was held at c/o...
Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib
02 avr. 2021 07h00 HE
|
Allarity Therapeutics A/S
- Submission precedes expected NDA filing for dovitinib in 2021 - Premarket Approval will allow U.S. marketing of DRP-Dovitinib as companion diagnostic to dovitinib Press release ...